Peptonic Medical’s rights issue oversubscribed
Stockholm, December 16th, 2015 - Peptonic Medical AB (publ) (“Peptonic Medical” or the “Company”) – a company developing pharmaceutical products based on oxytocin - has completed the rights issue as resolved by the extraordinary general meeting on November 19, 2015. The subscription period was from November 27 to December 11, 2015. The rights issue was oversubscribed and the Company receives approximately MSEK 22.7 before issuing costs of approximately 1.4 MSEK.
Approximately 94 percent of the rights issue were subscribed with preferential subscription rights. Subscription without preferential subscription rights amounted to approximately 14 107 425 MSEK. This resulted in a subscription rate of approximately 157 percent, which means that no commitments to underwrite will be utilized. The Company will receive approximately MSEK 22.7 before issuing costs through the rights issue.
Allotment of shares subscribed without preferential subscription rights have taken place in accordance with the principles set out in the information memorandum dated November 25, 2015. Notification of allotment is given by a contract note transmitted to the respective subscriber on December 17, 2015. The shares shall be paid in accordance with the instructions on the contract note.
The share capital in Peptonic Medical will increase with SEK 809 310.80 through a rights issue of 8 093 108 new shares. The Company’s share capital will amount to SEK 1 753 506.80 and the number of shares will be 17 535 068 after the rights issue.
Paid subscribed shares (BTA) in the rights issue will be traded on AktieTorget until the rights issue is registered with Bolagsverket and will be replaced by shares after this registration.
“I ‘m very pleased to see the successful completion of this rights issue and not least because of the high subscription rate. Preparations for the new study are well underway and we are confident to bring this project to a successful end. I want to thank our shareholders for all support and encouragement during this eventful autumn.”, says Johan Inborr, CEO of Peptonic Medical.
Advisors
Partner Fondkommission AB is acting as financial advisor to Peptonic.
For further information, please contact:
Johan Inborr, CEO
Phone: +46 708 853 893
E-mail: johan.inborr@peptonicmedical.se
About Peptonic Medical AB (publ)
Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal symptoms, such as vaginal atrophy. Oxytocin has a long history of safe medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women. Peptonic Medical AB (publ)’s mission is to develop safe and effective drugs based on oxytocin.